BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 980
- Registration Number
- NCT01217879
Real Life Safety and Efficacy of Vardenafil
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 372
- Registration Number
- NCT01215409
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Phase 2
Completed
- Conditions
- Constipation
- Interventions
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 154
- Registration Number
- NCT01212445
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2498
- Registration Number
- NCT01211171
LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 491
- Registration Number
- NCT01207947
Dose-confirmatory Bridging Study in Total Knee Replacement
Phase 3
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 302
- Registration Number
- NCT01206972
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17513
- Registration Number
- NCT01206257
Dose-confirmatory Bridging Study in Total Hip Replacement
Phase 3
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 402
- Registration Number
- NCT01205932
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: BAY86-9766 MEK Inhibitor + Sorafenib
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT01204177
Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: Gestodene/EE Patch (BAY86-5016)
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 173
- Registration Number
- NCT01204190